Tuberous sclerosis complex (TSC) is a rare genetic disorder associated with benign tumour formation. The disease is caused by loss-of-function mutations in either of the tumour suppressor genes TSC1 or TSC2. In normal cells, the proteins encoded by these genes collectively inhibit mTORC1 (mechanistic target of rapamycin complex I) signalling; when absent, mTORC1 signalling is increased. Paradoxically, in other disorders characterised by augmented mTORC1 signalling, overt malignancies are observed. Ess and colleagues exploited this difference to gain mechanistic insights into tumorigenesis. They established a zebrafish model of TSC that develops cancer, by generating tsc2;p53 compound mutants. Compared with p53 single mutants, tumorigenesis and angiogenesis were enhanced in tsc2;p53 zebrafish. Treatment with an mTORC1 inhibitor, rapamycin, inhibited tumour formation. This work provides in vivo evidence that cancer risk in p53-deficient individuals might be modulated by TSC1 or TSC2 mutations. Page 925
Insights into cancer risk from a tuberous sclerosis complex zebrafish model
- Split-screen
- Views Icon Views
-
Article Versions Icon
Versions
- Version of Record 01 July 2013
- Share Icon Share
-
Tools Icon
Tools
- Search Site
Insights into cancer risk from a tuberous sclerosis complex zebrafish model. Dis Model Mech 1 July 2013; 6 (4): 867. doi:
Download citation file:
Advertisement
Cited by
Special Issue: The RAS Pathway

Our latest special issue is now complete. It showcases RAS-driven mechanisms of disease progression, and highlights approaches to treat and modify the disease course in model systems.
Call for papers: Moving Heart Failure to Heart Success

Disease Models & Mechanisms is pleased to welcome submissions for consideration for an upcoming special issue, Moving Heart Failure to Heart Success: Mechanisms, Regeneration & Therapy. Submission deadline: 4 July 2022.
Propose a new Workshop

Our Workshops bring together leading experts and early-career researchers from a range of scientific backgrounds. Applications are now open to propose Workshops for 2024, one of which will be held in a Global South country. .
A focus on Drosophila

In a series of front section articles, DMM is highlighting the versatility, breadth, and scope of Drosophila research in human disease modelling and translational medicine.
Apply for a DMM Conference Travel Grant

Aimed at early-career researchers wanting to attend in-person and virtual meetings, the next application deadline for a DMM Conference Travel Grant is 6 June 2022. Find out more and hear from past recipients about their experience of the grant.
Other journals from
The Company of Biologists